ALK has been informed that the shareholders at an extraordinary general meeting of Fornix BioSciences (”Fornix”) today has approved ALK's proposal to acquire the Dutch activities of Fornix' Allergy Division, Artu, for a consideration of EUR 19.6 million (DKK 146 million). ALK made the proposal on 26 April 2010, cf. company release No 10/2010. The transaction will be effective on 1 July 2010, after which Artu and ALK's Dutch subsidiary will be fully integrated. No other approvals are outstanding, and ALK therefore considers the transaction finally approved. The acquisition is part of ALK's strategy of expanding its global presence and of contributing to the consolidation of the allergy vaccine industry caused by increased regulatory requirements to products. The acquisition is still expected to increase ALK's sales and earnings. The effect on operating profit (EBIT) after transaction costs in 2010 is expected to be slightly positive. ALK-Abelló A/S Jens Bager President and CEO For further information please contact: Jens Bager, President and CEO, tel. +45 4574 7576 Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Press: Martin Barlebo, tel. + 45 4574 7901, mobile + 45 2064 1143